Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Feedback plc (AIM: FDBK, “Feedback” or the “Company”), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018.
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
Clinigen Group plc today announces that it has completed the acquisition of CSM Parent, Inc. (‘CSM’), which was announced on 27 September 2018 (the “Acquisition”).
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 (the “Agreement”), to further improve the terms of its OCABSA financing program in the context of the closing of the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell, have now been completed as planned (see TxCell’s press release dated July 23, 2018). The OCABSA financing program is therefore terminated.
Immunicum AB today announced that Nasdaq Stockholm decided to halt trading in the Company’s share as a result of share price movements.
Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK.
Facility is acquired from Porton Pharma Solutions Ltd., and operated with GMP compliance.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.